Innogenetics secures key patent for hepatitis B drug resistance testing
08 Feb 2008 -
Innogenetics announced that the United States Patent Office has granted a key patent for hepatitis B drug resistance testing. This is the first granted US patent covering a critical mutation leading to hepatitis B viral drug resistance. US patent 7,313,357 covers an HBV virus with the YMDD mutation and, therefore, any method using this mutation for drug resistance testing. Drug resistance testing
is now highly recommended for all currently available hepatitis B antivirals such as lamivudine, adefovir, and entecavir. The patent broadens Innogenetics patent position in the field for at least 10 years.
Top
Contact
Print version
PDF version
Send article
RSS-Feed